Gamma Therapeutics, in a joint product development effort with Health Diagnostic Laboratory (HDL), has developed a CVD Risk Assay to enhance cardiologists' ability to assess heart attack and stroke risk by providing a new predictive and prognostic tool.
The laboratory developed CVD Risk Assay is based upon a naturally occurring clotting protein in human blood called Gamma Prime Fibrinogen, a biomarker strongly associated with cardiovascular disease.
The laboratory-developed test version of the Gamma Therapeutics’ CVD Assay will be offered exclusively by HDL, which also will take the lead in BETA testing of the assay for FDA approval.
Virginia-headquartered HDL CEO and co-founder Tonya Mallory said the partnership with Gamma Therapeutics demonstrates HDL ongoing goal to provide best of breed biomarkers, such as this new assay.
"Using a systematic approach to identify factors contributing to disease allows HDL, Inc. to provide its physicians with a better basis for effective treatment plans," Mallory said.